智通财经APP获悉，2024年，全球药品销售额排名预计将发生变动，艾伯维公司(ABBV.US)的Humira和辉瑞 (PFE.US )/BioNTech ( BNTX.US )的Comirnaty预计无法保持在前十名之内。取而代之的可能是诺和诺德 ( NVO.US ) 的2 型糖尿病药物 Ozempic和再生元制药( REGN.US )/赛诺菲 ( SNY.US ) 的Dupixent。Humir ...

BMS和默沙东方面则是主张维持现有的“全人群”适应症的标签。BMS的会议简报提到，不同药物的各项研究的评分方法和截断值存在差异，实施任何截断值都有可能让一部分患者失去获益的机会。

PD-1 inhibition before and after surgery for high-risk early triple-negative breast cancer (TNBC) led to significant ...

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

无论肿瘤的PD-L1表达如何，Opdivo和Keytruda都在这两种适应症中获得了批准。然而，FDA表示，越来越多的证据表明，PD-L1的表达可以作为药物在这一人群中疗效的预测性生物标志物。

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...

Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...

In KEYNOTE-522, treatment with neoadjuvant pembrolizumab and chemotherapy, followed by adjuvant pembrolizumab, led to ...

Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...

Discover the results from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, presented at ESMO 2024, Barcelona, Spain ...

NuCana的首席执行官兼创始人Hugh S. Griffith对USPTO的决定表示满意,称新专利进一步巩固了公司对NUC-7738的知识产权。他强调了令人鼓舞的临床数据,指出大多数PD-1抑制剂耐药性转移性黑色素瘤患者在接受NUC-7738和pembrolizumab联合治疗时,无进展生存期超过5个月。这一结果明显优于当前标准治疗2-3个月的中位无进展生存期。

结直肠癌（CRC）是一种常见的恶性肿瘤，在所有癌症中的发病率（6.1%）位居第三，死亡率（9.4%）居第二位。由于大肠癌的 ...